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Sexually Transmitted Infections, including Neisseria gonorrhoeae (NG) and Chlamydia tra-
chomatis (CT), continue to be a global health problem. Increased access to point-of-care-
tests (POCTs) could help detect infection and lead to appropriate management of cases
and contacts, reducing transmission and development of reproductive health sequelae. Yet
diagnostics with good clinical effectiveness evidence can fail to be implemented into routine
care. Here we assess values beyond clinical effectiveness for molecular CT/NG POCTs
implemented across diverse routine practice settings.
Methods
We conducted a systematic review of peer-reviewed primary research and conference
abstract publications in Medline and Embase reporting on molecular CT/NG POCT imple-
mentation in routine clinical practice until 16th February 2021. Results were extracted into
EndNote software and initially screened by title and abstract by one author according to the
inclusion and exclusion criteria. Articles that met the criteria, or were unclear, were included
for full-text assessment by all authors. Results were synthesised to assess the tests against
guidance criteria and develop a CT/NG POCT value proposition for multiple stakeholders
and settings.
Findings
The systematic review search returned 440 articles; 28 were included overall. The Cepheid
CT/NG GeneXpert was the only molecular CT/NG POCT implemented and evaluated in
routine practice. It did not fulfil all test guidance criteria, however, studies of test implementa-
tion showed multiple values for test use across various healthcare settings and locations.
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Our value proposition highlights that the majority of values are setting-specific. Sexual
health services and outreach services have the least overlap, with General Practice and
other non-sexual health specialist services serving as a “bridge” between the two.
Conclusions
Those wishing to improve CT/NG diagnosis should be supported to identify the values most
relevant to their settings and context, and prioritise implementation of tests that are most
closely aligned with those values.
Introduction
It is estimated that there are over 1 million new curable sexually transmitted infections (STI)
cases every day; in 2016 there were approximately 376 million new cases of the most common
curable STIs: Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT) Trichomonas vaginalis
(TV), and syphilis [1]. If left untreated, these infections can result in serious reproductive
health sequelae, such as infertility, chronic pelvic pain, ectopic pregnancy, and pelvic inflam-
matory disease. CT and NG infections are two key STIs: CT is the most commonly reported
STI [2], and treatment of NG is a global public health problem following the emergence of
multi-drug resistant strains [3].
Syndromic management (diagnosis and treatment of STIs based on patients’ clinical history
and reported and observed symptoms) has been shown to be both poorly sensitive and specific
for STI diagnosis [4]. It can result in asymptomatic but infected individuals not being treated,
resulting in continued transmission and development of reproductive health sequelae. Con-
versely, symptomatic patients of unknown aetiology may receive unnecessary, inappropriate
and/or sub-optimal treatment, potentially increasing the risk of STI antimicrobial resistance
(AMR) emergence [5]. STI diagnosis is therefore ideally informed by diagnostic tests, and
there has been a marked move away from syndromic management, wherever possible, in the
majority of high-income settings [6]. However, in LMICs, syndromic management is still com-
monplace. There is little access to large-scale laboratories, as well as a lack of highly skilled
healthcare professionals and specialised equipment in clinical settings, which are needed for
aetiological diagnosis of STIs [4, 5].
Diagnostics have been hailed as a critical intervention to reduce the global burden of AMR
[3], with a growing need for the development of point-of-care tests (POCTs) to combat the
global STI health burden [6, 7]. The World Health Organization (WHO) defines POCTs as
those that can be used at, or near, the point of patient care [8]. Guidelines and criteria for opti-
mal diagnostics have been published to both guide test development and assess their ability to
meet STI control requirements in all settings [9–12]. These include the REASSURED criteria
(Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free and Deliver-
able to end-users, recently updated to also include advances in m-health, incorporating both
“Real-time connectivity” and “Ease of specimen collection”) [9, 11]. These criteria focus on the
needs of LMICs and were developed by WHO’s STD Diagnostics Initiative as a benchmark to
determine whether POCTs for community level (level 1 health centres) use meet local require-
ments for STI prevention, control and management [13]. Furthermore, POCT Target Product
Profiles (TPPs) for specific infections have been created by WHO through consultation with
experts. These TPPs focus both on LMIC and higher-income country needs, and include
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multiple minimal and optimal characteristics, from diagnostic accuracy characteristics to cost
[12]. TPPs aim to help accelerate and guide future STI POCT development [12].
There are various POCTs for CT and NG diagnosis available [8, 14, 15]. Non-molecular
testing for NG includes Gram stain microscopy, which requires specialist equipment and a
high-level of training of healthcare professionals within the clinic [16]. For CT, commercial
antigen detection lateral flow tests have been developed with the ASSURED criteria in mind:
they are low-cost, equipment-free and easy to perform, but offer suboptimal sensitivity for
diagnosis [12, 17]. International guidelines stipulate that diagnosis of CT and NG should be
based on results from highly-accurate molecular tests wherever possible [18–21]. To date, two
highly accurate molecular POCTs for CT and NG have obtained Conformité Européene (CE)
marking from the European Union, and United States Food and Drug Association (FDA) reg-
ulatory approval, both of which offer CT/NG dual detection: the Cepheid GeneXpert, with a
90-minute time-to-results [22], and the binx health io with a 30-minute time-to-results [23].
However, even diagnostics with excellent clinical trial outcomes face multiple barriers to
adoption [24, 25]. Although TPP and REASSURED criteria are useful frameworks for test
development and evaluation, different values for adoption, such as clinical, process and finan-
cial outcomes, are negotiated during implementation [26]. It is increasingly recognised that
the social and structural context of implementing a new technology is as important as evidence
for its clinical effectiveness [27–29], and that these should be reviewed from the different per-
spectives of multiple stakeholders [24, 30, 31]. Stakeholders are defined as any person or orga-
nisation contributing to a care pathway, including patients, carers, healthcare professionals,
provider organisations, purchasers of healthcare services, policymakers and laboratory medi-
cine specialists [32].
The value of POCTs is likely to differ both within and between different stakeholder groups,
who often have varying priorities and objectives [33]. It is important to understand these val-
ues to facilitate the integration of POCTs into sexual healthcare. There are many proposed
frameworks to measure value [34], one of which is the value proposition of laboratory medi-
cine [35]. It aims to facilitate the implementation of innovations in healthcare by consolidating
and making visible the available evidence of the innovations’ costs and benefits to different
stakeholders [35]. It also considers values beyond clinical trial data, arguing that in an out-
comes-based health system, the value of an innovation to all stakeholders must be measured
and communicated [32, 35, 36].
We aimed to develop a value proposition for molecular CT/NG POCTs that is reflective of
the needs of different sexual healthcare stakeholders, in order to facilitate decision-making
processes for implementation and adoption of CT/NG POCTs into diverse care settings.
Methods
The overall research question was: “What are the outcomes of molecular CT/NG POCTs
implementation for patients being tested for CT/NG in different routine practice settings?” To
answer this question, we developed three specific objectives: i.) What values are placed on CT/
NG POCTs implemented in routine practice in the published literature? ii.) Do molecular CT/
NG POCTs implemented in routine practice fulfil the (RE)ASSURED and TPP criteria? iii.)
What is the value proposition for molecular CT/NG POCTs by setting, based on the value
proposition for laboratory medicine [35]?
To meet our first objective, we conducted a systematic review of the published literature
reporting on molecular CT/NG POCT implementation in routine clinical care. To meet the
second objective, we reviewed and assessed compliance of the tests identified through the sys-
tematic review to REASSURED and TTP criteria for STI POCT development, using data from
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formal diagnostic evaluations. For the third objective, we developed a CT/NG POCT value
proposition based on a synthesis of the wider available evidence. Data from additional studies
evaluating NAAT-based test(s) for CT/NG, but that were ineligible for the systematic review
(e.g. research-only outcome, such as diagnostic accuracy studies; or not primary research, such
as cost-effectiveness modelling), were extracted. These were applied to the value proposition
for laboratory medicine framework [35] to develop a value proposition for molecular CT/NG
POCTs, by setting type. Data were tabulated to meet each objective, and a narrative synthesis
of results (i.e., rather than a metanalysis) was conducted by SSF and EMHE, given the hetero-
geneity of study designs and settings.
The systematic review was conducted in MEDLINE and Embase (OvidSP interfaces) to
include all peer-reviewed primary research and conference abstract publications until 16th
February 2021 (S1 and S2 Tables). Both MEDLINE and Embase (OvidSP interfaces) were
searched by one researcher (EC) for studies involving human participants using a combination
of terms and synonyms based on four key concepts (chlamydia AND gonorrhoea AND point
of care tests AND evaluation). For full details of search terms please see S1 Table. We report
our review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [37] (S2 Table).
Results were extracted into EndNote (Clarivate Analytics, Philadelphia, USA), and dupli-
cates removed. Titles and abstracts were screened by EC according to the inclusion and exclu-
sion criteria (Table 1). Articles that met the criteria, or any that were unclear, were included
for full text review by all authors independently, with any discrepancies discussed as a group to
reach consensus for final inclusion. SSF and EMHE independently extracted data from eligible
articles into custom-made Excel (v2019, Microsoft) tables. References of included papers were
also hand-searched by EC and new potentially eligible articles full-text screened by all authors
before confirming inclusion, with data independently extracted by SSF and EMHE.
Study quality was assessed by SSF and EMHE, independently, using the Critical Appraisal
tools for use in JBI Systematic Reviews where possible ([38] as recommended by [39]; S3–S7
Tables). For studies where the CT/NG POCT was implemented as routine (e.g. service evalua-
tions), we modified the JBI checklist for analytical cross-sectional studies by removing the
three questions relating to exposure and confounding, as no JBI checklists were appropriate.
For before-after studies, the NHLBI quality assessment tool was used [40]. For questionnaire-
based studies, the Center for Evidence-Based Management “Critical appraisal of a survey”
checklist was used ([41] as recommended by [42]). Any differences between the two reviewers
were reconciled through discussion to provide an overall study quality score calculated as
number of questions with a “yes” response divided by the total number of questions. Any ques-
tions that were non-applicable were removed from the denominator.
We did not produce a protocol or register this study.
Results
The systematic review search returned 440 articles, of which 26 were included for review. After
the references of the 26 included articles were checked to confirm completeness, two further
articles were eligible, which led to a final inclusion of 28 articles (Fig 1). Study quality assess-
ment indicated that 5 studies were of low quality (�50% criteria met), 4 studies were of
medium quality (between 50 and 75% of criteria met) and the remaining 19 articles were of
high quality (�75% criteria met) (S3–S9 Tables).
The binx health io CT/NG has been implemented in a small number of clinical settings,
however, available reports show the test being implemented in research-use only scenarios in
the USA [43, 44] and publications (to-date of this review) reporting implementation in the UK
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do not report clinical and other health-related outcomes [45]. The Cepheid CT/NG GeneXpert
has been implemented and evaluated for multiple outcomes measures in many settings around
the world. As such, only the Cepheid GeneXpert platform, using the CT/NG dual diagnostic
cartridge, was eligible for assessing compliance with international guidelines for CT/NG
POCT development and evaluation, and evaluating the values placed on CT/NG POCTs
implemented in routine practice in the published literature.
TPP and REASSURED criteria provide checklists to guide the development and evaluation
of STI POCTs. A summary of both these frameworks for CT/NG POCTs is presented below
Table 1. Inclusion and exclusion criteria.
Inclusion Exclusion
Population • Humans • Non-humans
Intervention • Point of care or rapid tests Tests for combined genital chlamydia and
gonorrhoea detection.
• Implemented as routine practice
• Tests that are not classed as point of care or rapid
• Tests that are not nucleic acid amplification tests
• Tests for infections other than genital chlamydia and gonorrhoea
• Tests that only detect chlamydia OR gonorrhoea
• Tests that are not Conformité Européene (CE)- or Food and Drug
Association (FDA)- approved
• Tests not implemented as routine practice, e.g. implemented as a
research-only tool
Outcome • Evaluation of the implementation of the test as in routine practice (e.g.
time to treatment)








• Any other type of literature
Date • Articles published up to 16/02/21 • Articles published after 16/02/21
Language • Any • Any
https://doi.org/10.1371/journal.pone.0259593.t001
Fig 1. PRISMA flowchart [37]. From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD,
et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.
1136/bmj.n71. For more information, visit: http://www.prisma-statement.org/.
https://doi.org/10.1371/journal.pone.0259593.g001
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(Table 2); these reflect a summary of published evaluations of the Cepheid CT/NG GeneXpert
diagnostic performance.
TPP recommendations for CT/NG POCTs
WHO TPP recommendations for CT/NG POCTs include: sensitivity (NG: 90% minimal, 98%
optimal; CT: 90% minimal, 100% optimal) and specificity (NG and CT: 98% minimal, 100%
optimal); training requirements (<90 minutes minimal, <30 minutes optimal); time-to-
results (<60 minutes minimal, <30 minutes optimal) and price per test (<5 USD minimal,
<1 USD optimal) [12]. Other considerations include the inclusion of a Global Positioning Sys-
tem (GPS) on the platform reader, and sample capacity/through-put [12]. Operational use
prioritisation is suggested to be in the following order: ease of use, training, high tolerance to
Table 2. The Cepheid CT/NG GeneXpert fulfilment of TPPs and REASSURED criteria.
Characteristic�
Sensitivity/specificity genital samples (a,b) Sample type CT % sensitivity /
specificity
NG % sensitivity /
specificity
Male Urine 97.5 / 99.9 98.0 / 99.9
Female endocervical
swab
97.4 / 99.6 100.0 / 100
Female vaginal swab 98.7 / 99.4 100.0 / 99.9
Female Urine 97.6 / 99.8 95.6 / 99.9
Pooled percent agreement extra-genital samples (a,b) Sample type CT % agreement positive
/ negative
NG % agreement positive
/ negative
Rectal 89.72% / 99.23% 92.75% / 99.75%
Pharyngeal 89.96% / 99.62% 92.51% / 98.56%
Use setting (a,b) Table-top, not portable
Level 2 service (district hospital)
Specimen (a,b) Female and male urine, endocervical swab, vaginal swab, rectal swab and
pharyngeal swab from asymptomatic and symptomatic patients
Steps; user-friendly (a,b) ~4; sample preparation automated. Three-step process from sample
provision to processing; sealed cartridge system; <1 minute hands-on time
Time to result (run-time) (a,b) ~90 mins
Cold chain; reagent stability (a,b) No; to be determined
Power (a,b) Mains power or solar power
Training; user-friendly (a,b) Less than half a day
Connectivity for monitoring, surveillance & data export (a,b) Yes; computer/internet required; remote calibration; C360 platform system
provides systems and epidemiology monitoring. Connectivity between
GeneXpert and electronic patient records used to deliver results in published
service evaluation [47].
Equipment price (USD); per test price (a,b) ~17,000 USD (with 4 modules), but could be higher; 16.20 USD (CT/NG)
Environmentally friendly (a,b) No: single use cartridge; disposal of used materials via local medical waste
regulations
Environmental tolerance of packaged test kit and operating conditions (robust—
tolerance to difficult environmental conditions) (a,b)
Stable temperature and power required but has been used successfully in
remote healthcare settings (see Table 3)
Internal quality control (a) Yes. Sample Adequacy Control on each cartridge for increased results
integrity
Sample capacity/through-put (a) Various capacity readers available (single to 80 cartridge units); readers
stackable for scale-up
�a = TPP; b = REASSURED [8, 11, 12, 46–51].
https://doi.org/10.1371/journal.pone.0259593.t002
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difficult environmental conditions and long shelf life, self-contained quality control, data cap-
ture/connectivity/data export, biosafety and waste disposal [12].
REASSURED criteria
The REASSURED criteria are: Real-time connectivity (feedback for patient treatment and
connection to surveillance systems); Ease of specimen collection and Environmentally-
friendly (non-invasive specimen collection; use of recyclable materials and reduction of haz-
ardous waste); Affordable (<10.00 USD for a molecular assay); Sensitive (minimising false
negatives) and Specific (minimising false positives); User-friendly (2–3 steps and minimal
training required); Rapid and robust (15–60 minutes from sample-in to answer-out; with-
stands various weather and environmental conditions without refrigeration); Equipment-free
(or utilises batteries or solar power) and Deliverable to end-users (ensures it reaches LMIC
users) [11].
Published diagnostic evaluations show that the Cepheid CT/NG GeneXpert fulfils some,
but not all, TPP and REASSURED criteria (Table 2). Minimal sensitivity and specificity
requirements are met for genital samples, but not for extra-genital samples for CT. Training
may be considered too long at “less than half a day”, compared with the minimal TPP require-
ment for <90 minutes. The 90-minute time-to-results is longer than the 60-minute minimum
of both criteria frameworks, and the cost is higher than the 10 USD recommendation for the
REASSURED criteria. In addition, the test is not environmentally friendly, as it uses a single-
use cartridge to be disposed of via local medical waste regulations. However, the test can be
used with non-invasive specimen types, does feature connectivity for monitoring, surveillance
and data export, and is user-friendly with automated sample preparation and a three-step pro-
cess from sample provision to processing. It also features a sample adequacy control for inter-
nal quality control purposes. The REASSURED criteria “deliverable to end-users” can be
considered contextually, such as the tests’ compatibility with diagnostics currently in use (e.g.
current use of the GeneXpert platform for tuberculosis or TV testing [46]), which relate to
potentials to use pre-existing procurement and test supply chains in those settings.
Data from eligible articles were extracted to show the value of implementing the Cepheid
CT/NG GeneXpert in three different healthcare service settings (specialist sexual health ser-
vices, General Practice [GP] and other non-sexual health specialist services, and outreach ser-
vices), spanning different income settings (Table 3).
Implementation of the Cepheid CT/NG GeneXpert demonstrated that faster (and appropri-
ate) treatment was achieved in all settings. This was facilitated by reduced time to notification
of results, which was a specific outcome for some studies [47, 58, 60, 63, 69] but same-day
treatment was hindered by patients not waiting for test results at the point of care [61, 65], and
one study specifically reported increased patient waiting time in-clinic [57]. However, imple-
mentation of the test was broadly acceptable in all settings reporting this as an outcome [55,
61, 66–68, 72]. In non-sexual health services, introduction of the Cepheid CT/NG GeneXpert
enabled detection of STIs, a service which previously had not been available [57, 64, 66, 67,
69]. Additional benefits beyond immediate patient management were also recorded, including
improving partner treatment, reducing transmission, and cost-savings [47, 55, 65, 69].
In Table 4, in addition to the Cepheid CT/NG GeneXpert studies included in Table 3, we
report on a wider literature of stakeholder values for implementation of POCTs, including
reports of the binx health io CT/NG. Studies reporting implementation of the binx CT/NG in
a sexual health specialist service and a University student health clinic (outreach service) in the
USA were restricted to implementation without results delivery; at the time of the studies the
test was not yet FDA approved [43, 44, 73]. Publication of a UK-based project tracing
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Table 3. Routine implementation of the Cepheid CT/NG GeneXpert in different healthcare service settings.
Care setting Study design and location Target population Test Implementation Impacts assessed Results
Sexual health services GeneXpert test implementation
and time to treatment comparison
with same target population. San
Francisco City STI Clinic, USA.
May-Dec 2018. Cohen et al. 2019.
Asymptomatic MSM and transwomen
attending follow-up care for HIV PrEP;
those who were sexual contacts of
someone with CT/NG were excluded
GeneXpert implementation as standard
of care among MSM and transwomen
1. Mean and median time to
treatment
1. 90 patients were NG/CT positive. After
introduction of POCT, mean and median time
to NG/CT treatment decreased from 6 and 4
days to 1.7 and 0 days (p<0.001)
Comparison of standard care with
“sample-first” (prior to
consultation) pathway and use of
in-house GeneXpert testing on
patient management. Courtyard
Clinic, St George’s University
Hospitals NHS Foundation Trust,
London UK. Harding-Esch et al.
2017.
Males and females symptomatic for CT/
NG infection; sexual contacts of CT/NG
positive patients
Standard triage procedure followed by
self-collected sample provided by
patients prior to clinical consultation.
GeneXpert testing, routine culture and
microscopy, and non-NAAT POCTs for
TV and BV. Results provided to patients
in clinical consultation
1. Proportion of patients
who responded in favour
of the ‘sample first’
approach
2. Proportion of patients
who received test results in
the same clinical visit







1. 95.8% (23/24) of patients found self-sample
provision prior to clinical consultation
acceptable; no patients refused
2. 78.6% (55/70) of patients did not wait for POCT
results before leaving clinic
3. GeneXpert results (CT/NG negative) led to: two
females avoiding presumptive treatment; one
male receiving treatment for possible
Mycoplasma genitalium infection
Implementation of GeneXpert in
specialist sexual health clinic
symptomatic service in London,
UK. No dates given. Mandlik et al.
2017.
Subset of 100 symptomatic patients
diagnosed with CT/NG
GeneXpert implementation as standard
of care
1. Time from attendance to
treatment
2. Modelled number of
partners not exposed due
to earlier CT/NG
treatment of index patient
1. Time to treatment reduced by 66% (6.2 days)
from 9.5 days pre-implementation to 3.3 days
post-implementation.
2. 54% fewer partners were exposed to CT/NG
(19.9 pre-implementation and 9.12 post-
implementation)
Retrospective review of patients’
notes in sexual health clinic after
GeneXpert introduction, London,
UK. No dates given. Whitlock
et al. 2015.
Patients diagnosed with CT/NG Service redesign involving express
screening service, including sexual
history on touchscreen computers, self-
collected samples, POC testing and
automated results management
1. Time to treatment 1. Of 431 CT and/or NG diagnoses, time to
treatment reduced by 190 hours
Comparison of data between Dean
Street Express (DSE; a walk-in,
rapid STI screening service for
asymptomatic individuals) and 56
Dean Street (56DS; standard off-
site laboratory-based NAAT
testing), London, UK, in one-year
period from 1 June 2014 to 31 May
2015. Whitlock et al. 2018.
Patients attending DSE and 56DS. Data
extracted from patient notes of first 12
patients (MSW, MSM and women)
GeneXpert implementation as standard
of care at DSE. Sexual history is
provided by patients on a touchscreen
computer, which orders the relevant
swabs based on self-reported sexual
history. Patients self-collect swabs/
samples, which are delivered to and
processed on-site GeneXpert. Health
adviser reviews sexual history, collects
blood for off-site syphilis, HIV and/or
hepatitis B/C testing (results within 4
hours). Treatment for test-positive
patients is provided at 56DS
1. Time from sample
collection to notification
of GeneXpert test results




3. Modelled cost to clinics of
fewer attendances for
screening and treatment of
partners
4. Modelled potential public
health impact due to
transmissions averted
1. Time from sample collection to notification of
GeneXpert test results for 138,261 test
notifications reduced by 8.68 days between 56DS
[8.95 days (95% CI 8.91–8.99 days)] and DSE
[0.27 days (95% CI 0.26–0.28 days)]
2. Estimated 854 partner attendances averted
3. Estimated annual savings of £124,283 (IQR
£4260–590,331) due to reduced partner
attendances
4. Estimated 196 CT and/or NG transmissions
averted
Comparison of standard care and
use of in-house GeneXpert testing
and results notification pathway.
Dean Street Express clinic, Chelsea
and Westminster Hospital NHS
Foundation Trust, London UK. 19
April 2013–7 January 2014.
Wingrove et al. 2014.
Males and females asymptomatic for
CT/NG infection
GeneXpert introduced into clinic for
on-site testing
1. Median time from testing
to treatment for positive
patients
2. Median time to informing
of results for negative and
positive patients
3. Median time from
informing positive
patients of results to
treatment
1. Median time from testing to treatment for
patients with positive results (n = 28) was 2 days
(IQR 1–6 days) with GeneXpert and 10 days
(IQR 7–11 days) for standard care
2. Median time to informing of negative results
(n = 50) was 1 day (IQR 1–2 days) for
GeneXpert and 12 days (IQR 8–14 days) for
standard care. Median time from testing to
patient result delivery for positive patients was 1
day (IQR 1–3 days) with GeneXpert and 8 days
(IQR 7–9 days) for standard care
3. Median time from informing patients to
treatment was 1 day (IQR 0–2 days) with
GeneXpert and 1 day (IQR 1–4 days) for
standard care
(Continued)
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Table 3. (Continued)
Care setting Study design and location Target population Test Implementation Impacts assessed Results
General Practice and other
non-sexual health specialist
services
Assessment of introducing newly
available STI POCTs and
treatment. Alotau, Milne Bay
Province, Papua New Guinea.
August—December 2014. Badman
et al. 2016
Females�18 years attending their first
clinic antenatal visit
Face to face interview with nurse:
demographic and sexual behaviour data
collection. Routine antenatal and
provider-initiated HIV (Alere
Determine HIV1/2) and syphilis (SD
Bioline anti TP 3.0) screening via rapid
test; Syphilis rapid test followed by
confirmatory laboratory test. Self-
collected vaginal swabs with on-site
testing for CT/NG and TV (Cepheid
GeneXpert) and BV (BV Blue). Positive
patients (as needed): same-day
antibiotic treatment; risk-reduction
counselling; contact tracing
1. Impact of introducing
newly available STI
POCTs on patient waiting
times
2. Proportion of patients
receiving same-day results
3. Proportion of participants
positive for infection




5. Reasons for leaving prior
to treatment
1. Integration of study procedures into routine
clinic activities resulted in an average of two
hours’ additional waiting time per patient
2. All participants (n = 125) received same-day
results
3. 53.6% (67/125) of patients had CT, NG, TV or
BV; of these 71.6% (48/67) were asymptomatic
4. Of those with an infection, 83.6% (56/67)
received same-day treatment. All received
treatment within one week.
5. Reasons for leaving prior to treatment included
family commitments, and the need to travel
significant distances back to their homes by foot
or by bus
Assessment of introducing
GeneXpert into two university
hospital family planning clinics:
Antoine Béclère Hospital
(Clamart, France) and Avicenne
Hospital (Bobigny, France), July
2012—Jan 2013. Bourgeois-
Nicolaos et al. 2015.
Women presenting to the clinics for
induced abortion, intrauterine device
insertion as emergency contraception,
or signs of STI, were consecutively
recruited
Patient samples sent for GeneXpert
testing in hospital’s laboratory. Test
results reported to clinic by phone and/
or fax. Patients with positive results
were immediately telephoned and
prescription faxed to their closest
pharmacy. Prescriptions for partners, or
letter to partner’s physician, provided
1. Test success rate




1. The rate of GeneXpert assay success was 98.3%
(581/591) test success (not intermediate/invalid
result) on first attempt
2. 100% of patients received appropriate treatment
pre-termination procedure, compared with 40%
with standard NAAT
Assessment of GeneXpert
implementation in Haitian Study
Group for Kaposi’s sarcoma and
Opportunistic Infections
(GHESKIO) clinics. GHESKIO
provides “integrated primary care
services, including HIV
counselling, AIDS care, antenatal
care, and management of
tuberculosis and STIs.” Port-au-
Prince, Haiti, 26 Oct 2015–14 Jan
2016. Bristow et al. 2017.
Pregnant women�18 years attending
GHESKIO clinics
Participants self-collected samples,
which were tested by GeneXpert as
standard of care. Women returned to
GHESKIO within 7 days to receive test
results and treatment if test-positive
1. Proportion of patients
consenting to participate
(acceptability)
2. Proportion of infections
treated (feasibility)
1. 300/322 (93.2%) women consented to testing
2. 122/133 (91.7%) infections were treated
Assessment of GeneXpert test
implementation in Prince Cyril
Zulu Communicable Disease
Centre (PCZCDC), a large public
healthcare clinic that provides
“general primary health care
services for adults free of charge”
in Durban city centre, KwaZulu-
Natal, South Africa, May 2016—
Jan 2017. Garrett et al. 2018.
HIV-negative women, at high HIV risk,
aged 18–40 years, attending PCZCDC
for STI care
Implementation of GeneXpert,
Trichomonas vaginalis (TV) (OSOM1
Rapid Trichomonas Test), and bacterial
vaginosis (BV) (Gram stain microscopy)
to evaluate how expedited partner
therapy (EPT) introduction could be
accelerated through use of POCTs.
Results available within 2 hours. Test-
positive women were immediately
treated and offered EPT packs. STI-
positive women invited to participate in
focus group discussions on POC testing
and EPT. An EPT questionnaire was
administered by telephone at one-week
follow-up. Women were retested for
STIs in the clinic after 6 and 12 weeks.
1. Proportion of STI-positive
women accepting EPT
2. Proportion of STI-positive
women successfully




1. 62/63 (98.4%) women with an STI were offered
EPT, and 54/62 87.1% accepted
2. At telephonic follow-up one week later, 48/54
(88.9%) reported successfully delivering EPT to
partner at one-week follow-up (77.8% [42/54]
observed; (11.1% [6/54] unobserved)
3. In focus group discussions, women (n = 29)
reported being in favour of the new care model
acceptable and supported the care model
because “they received a rapid, specific
diagnosis, and could facilitate their partners’
treatment”
Randomised controlled trial in an
urban academic emergency
department (ED), USA. April 2015
—May 2016. Gaydos et al. 2019.
Women undergoing pelvic
examinations and CT/NG testing as
part of their ED standard of care
Control: standard-of-care CT/NG
NAAT, with 2- to 3-day turnaround
time.Intervention: rapid GeneXpert test,
in addition to the standard-of-care
NAAT. Rapid results immediately
provided, and treatment provided to all
patients according to providers’ clinical
judgment
1. Proportion of patients
under-treated
2. Proportion of patients
over-treated
3. Length of stay
1. Undertreatment for CT/NG was 0% for the
intervention group (0/10 & 10/5) and 43.8% (6/
13 and 4/7) for the control group
2. Clinicians unnecessarily provided treatment for
CT in 46.5% (53/114) of uninfected control
group participants compared with 23.1% (27/
117) of intervention group participants.
Clinicians unnecessarily provided treatment for
NG in 46.7% (56/120) of control group
participants compared with 25.4% (31/122) of
intervention group participants
3. The length of stay did not differ significantly
between groups
(Continued)
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Table 3. (Continued)
Care setting Study design and location Target population Test Implementation Impacts assessed Results
Cross-over cluster randomised
controlled trial of routine
GeneXpert implementation to
improve infection management
(intervention; n = 6 health
services) compared to standard
care (control; n = 6 health
services). Primary health services
that provide care to Indigenous
people in regional or remote
locations in Western Australia, Far
North Queensland, and South
Australia. June 1, 2013—Feb 29,
2016. Guy et al. 2018.
Patients aged 16–29 years attending
participating health services in a
12-month period
Health services were provided training
for use of the GeneXpert and
equipment, supplies for �150
GeneXpert tests; participating services




found to have CT or NG
who had a positive result
at retesting 3 weeks to 3
months after treatment
2. Secondary outcomes:
3. Proportion of infections
treated within 7 days of
sample collection date;
4. Proportion of patients
who were given treatment
on the same day as testing
5. Proportion of patients
who were given treatment
within 2 days of testing
6. Proportion of patients
who were given treatment
within 7 days of testing
7. Proportion of patients
who were given any
treatment within 4 months




1. Proportion of positive-test individuals retested
between 3 weeks and 3 months after treatment
was: 14% (63/455) in intervention group (19%;
12/63 had positive retest result) versus 17% (67/
405) in control group (13%; 9/67 had a positive
retest result)
2. Of all individuals with a positive test in the
intervention group, 76% (347/455) were treated
within 7 days compared with 47% (191/405) in
the control group (absolute across-cluster
difference of 29%)
3. In the intervention group, 49% (221/455) were
given treatment on the same day as testing
compared with 27% (111/405) in the control
group
4. In the intervention group 60% (274/455) of
patients were treated within 2 days, compared
with 30% (122/405) in the control group
5. In the intervention group 76% (347/455) of
patients were treated within 7 days, compared
with 47% (191/405) in the control group
6. In the intervention group 94% (427/455) of
patients were treated within 4 months,
compared with 86% (347/405) in the control
group
7. Clinical staff (N = 35) found GeneXpert testing
highly acceptable
8. Patient acceptability surveys (N = 80) indicated a
high degree of satisfaction with GeneXpert
testing
Randomised controlled trial in an
urban ED, Washington DC, USA,
Oct 2013—Oct 2014. May et al.
2016.
Symptomatic patients presenting to an
urban ED, and where treating provider
was ordering diagnostic CT/NG test
Control: standard-of-care CT/NG
NAAT, with results available within 1–4
days Intervention: rapid GeneXpert test,
with results provided during ED visit.
Treatment was provided at ED
provider’s discretion. After patient





3. Symptom resolution 7 to
10 days post-discharge
4. Results notification
5. Healthcare utilisation and
charges, and total ED
charges
1. Clinicians unnecessarily provided treatment for
CT and/or NG to 11/20 (55.0%) control group
participants, compared with 8/37 (21.6%)
intervention group participants (P = 0.01)
2. intervention group participants were less likely
to report missed antibiotic doses (Risk
Difference [RD], −51.3%; 95% CI, −84.4% to
−18.2%; Risk Ratio [RR], 0.23; 95% CI, 0.06–
0.88)
3. No differences were found in symptom
resolution 7 to 10 days post-discharge between
intervention and control group participants
4. Intervention group participants were more likely
to be notified of their results (RD, 50.6%; 95%
CI, 22.7%–78.5%; RR, 2.72; 95% CI, 1.26–5.86)
5. There were no significant differences in
healthcare charges or utilisation, or total ED
charges
Assessment of GeneXpert
introduction in antenatal clinic
(ANC), Kinshasa, Kisantu health
zone, Democratic Republic of
Congo. No dates given. Mvumbi
et al. 2017.
Pregnant women attending ANC Trained clinic staff collected observed if
women presented with STI symptoms,
and collected vaginal swabs. Samples






1. 10/352 (2.8%) women were symptomatic; 5/10
(50%) were CT/NG/TV positive
2. 50/342 (14.6%) asymptomatic patients were CT/
NG/TV positive
Comparison of patients tested with
GeneXpert C to a historical
control group tested using a
traditional NAAT in an urban
community teaching hospital ED,
Dec 2014–Jan 2015. Rivard et al.
2017.
Patients�15 years of age who were
tested for NG/CT
GeneXpert implementation as standard
of care. Test-positive patients who
received results prior to ED discharge
were provided with notification,
counselling, and treatment on-site. For
patients whose results were not available
pre-discharge, providers could offer
empiric treatment and then follow-up
with results post- discharge
1. Percentage of patients who
received appropriate
initial treatment during











3. Time to test results
4. Time to patient
notification of positive test
results
5. Time to appropriate
treatment
6. Cost of appropriate and
inappropriate treatment
200 consecutive patients tested by GeneXpert
compared with 200 historical patients tested with
traditional NAAT.
1. 60% of patients received appropriate initial
treatment in the historical group, compared with
72.5% in the GeneXpert group (P = 0.008). This
was predominantly due to avoiding unnecessary
treatment test-negative patients
2. CT/NG test availability prior to discharge was
the only factor associated with appropriate
treatment (odds ratio [OR], 22.65 [95%CI, 2.86–
179.68, P = 0.003])
3. Median time to test results was 2.4 hours (1.4–
12.0) in the GeneXpert group compared with
31.7 hours (9.7–105.9) in the historical group
(P<0.001)
4. Median time to patient notification of positive
test results was 17.4 hours (0.0–93.0) in the
GeneXpert group compared with 53.7 hours
(26.9–79.9) in the historical group (P = 0.010)
5. Mean time to appropriate treatment for test-
positive patients was 4.9 ± 21.3 hours in the
GeneXpert group compared with 23.0 ± 56.3
hours in the historical group
6. GeneXpert testing cost $343,566 over the study
duration compared with $348,457 in the
historical group, saving $4891 ($24.46 per
patient)
(Continued)
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Table 3. (Continued)
Care setting Study design and location Target population Test Implementation Impacts assessed Results
Assessment of GeneXpert
implementation in Princess
Marina Hospital ANC (the main
government referral hospital for
southern Botswana), Gaborone,
Botswana, July—October 2015.
Wynn et al. 2016.
Women receiving antenatal care at the
clinic, who were aged�18 years,
gestational age <35 weeks, mentally
competent and willing to return to
clinic for follow-up care
Women self-collected vaginal swabs,
which were tested on-site in the ANC
vitals room by GeneXpert for CT, NG,
and TV. Women received same-day test
results notification, in-person or by
telephone. Test-positive women




2. Feasibility of intervention
3. Treatment uptake
1. 200/225 (89%) eligible women accepted to
participate.
2. 100% of eligible women were successfully tested
for CT, NG and TV, and received same-day
results. 143 (72%) women received results in-
person prior to leaving clinic, and 57 (29%) were
contacted by telephone after leaving the clinic (6
[10.5%] of these were test-positive and returned
to clinic for treatment)
3. 100% of test-positive women were successfully
treated, 80% immediately
Assessment of GeneXpert
introduction in one main clinic
and three sex-on-premises venues
(SOPV) where regular outreach
HIV/syphilis POC testing had
been taking place, within an urban
community context, Brisbane,
Australia, 3 March 2017–14 June
2018. Bell et al. 2020.
Prospective consecutive sampling of
asymptomatic patients (predominantly
MSM),�16 years, presenting at any of
the four included locations. Patients
reporting potential HIV exposure
within the past 72 hours of attendance
were excluded
Pilot of peer-delivered, community-led
service providing POC CT/NG testing.
GeneXpert implementation as standard
of care in included settings. Participants
self-collected samples, which were
tested by GeneXpert at main clinic.
Participants received their CT/NG
results by telephone or SMS within 24 h.
Test-positive participants referred for
treatment, either in-clinic or elsewhere
(community-based services, sexual
health services, regular GP and non-
regular GP). Peer test facilitators
conducted follow-up telephone
interviews with test-positive
participants 2 weeks post-referral for
retesting and treatment. Additional
online ‘Post-Referral Survey’ for test-
positive participants at 2-week post-
testing follow-up interview phone call.
1. Acceptability and
feasibility
2. Time to results
notification
3. Proportion of treated
patients




1. CT/NG POCT accepted on 93.4% (4523/4843)
occasions; 99.3% of patients accepted on their
first visit. Uptake varied by setting: 93.8% (4051/
4318) at clinic vs. 89.9% (472/525) from the
three SOPVs combined (P<0.001). Post-Referral
Survey and Evaluation Survey results indicated
patients found the service acceptable, accessible,
and would recommend the service.
2. 604/614 (98.4%) test-positive participants
received their result and were referred for
treatment within 24 h of testing. Ten (1.6%)
were ‘lost to follow up’
3. 89.7% (70/78) of participants reported receiving
treatment
4. Post-referral, 64.1% (50/78) of participants
reported informing all their contacts
5. Estimated 117 CT and 66 NG infections would
not have been identified if the service was not
offering CT/NG testing
Outreach services Assessment of GeneXpert
implementation in a mobile
healthcare van at an annual
community event in a
metropolitan area with high STI
prevalence. 2012 and 2013, no
specific location given. Hesse et al.
2015.
Males and females�14 years All specimens were self-collected in the
van. Participants with positive results
were notified and prescribed treatment.
Questionnaire to assess acceptability of
test turnaround times and self-sample
collection
1. Treatment delivery rates
2. Patient acceptability of
testing
1. 2/12 (16.6%) females and 0/10 (0%) males were
CT positive and none were NG positive using
GeneXpert testing. 1/2 (50%) positive patients
was notified of her results and received same-
day treatment
2. 30 participants (20 females; 10 males) completed
the questionnaire. Sample collection was as
acceptable in a van as in the doctors’ office;
faster turn-around-times for STI testing results
were considered the most acceptable
Assessment of GeneXpert
introduction and same-day CT/
NG treatment. May 2017 to June
2019, Los Angeles California and
New Orleans Louisiana, USA.
Keizur et al. 2020.
Young people ages 12–24 years with
high sexual risk behaviours, recruited
online and in advertisements in
homeless shelters, lesbian, gay, bisexual,
and transgender organizations and
community health centres in Los
Angeles, California, and New Orleans,
Louisiana USA
Every 4 months, within a 24-month
enrolment period, participants attended
clinic and self-collected pharyngeal,
rectal, and urine or vaginal samples for
CT/NG testing using GeneXpert.
Positive patient management: Before
March 2018 in Los Angeles and
November 2018 in New Orleans:
participants were referred to a local
clinic or their primary care doctor for
treatment. After March 2018 in Los
Angeles and between 12 November
2018 and 28 February 2019 in New
Orleans: participants were offered same-
day treatment and expedited partner
therapy packs by study staff
1. Proportion of participants
who received same-day
treatment
2. Participants’ median time
to treatment
3. Number of partner
treatment packs taken by
participants
4. Any reported adverse
treatment-related events
1. The proportion of participants receiving same-
day CT and NG treatment increased from 3.6%
(5/140) pre-intervention to 21.1% (20/95) post-
intervention
2. Median time to treatment decreased from 18.5
days pre-intervention to 3 days post-
intervention
3. 37.9% (n = 36) participants took a median of 1
partner treatment pack each (range 1–3; 48
total)





in CHIEDZA trial (Community
based interventions to improve
HIV outcomes in youth), June
2019—Jan 2020. Martin et al. 2021.
All youth, aged 16–24 years, accessing
CHIEDZA services.
GeneXpert testing within 48 hours of
first-catch urine sample provision.
Participants able to collect test result the
following week, with positive-test
participants actively followed-up.
1. STI testing uptake
2. Proportion of test-positive
participants treated
3. Proportion of test-positive
participants symptomatic.
4. Contacts traced and
treated
5. Factors associated with
testing uptake
1. Uptake was 33�3% (1478/4440; 95% CI 31�9–
34�7); 30�4% (294/967) in men and 34�1% (1184/
3473) in women
2. 67% (165/248) test-positive participants treated
3. 3% (7/248) test-positive participants
symptomatic and received syndromic
management
4. 87/248 (35.1%) partners attended for treatment
5. Current STI symptoms were independently
associated with testing uptake. Uptake also
motivated by potential to be treated if positive,
and perceived risk based on their own or
partner’s sexual behaviour. Stigma and lack of
confidentiality were barriers to testing.
(Continued)
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implementation into routine care did not include assessment of clinical outcomes [73]. Never-
theless, the available studies (albeit limited to the USA and UK) have shown implementation
processes of this CT/NG POCT to be highly acceptable to patients [43, 44] and healthcare
workers [44, 45, 73].
Some of the values for molecular CT/NG POCTs cross-cut all settings: unmet need, care
pathway context, and accountability. However, the majority of values are setting specific. Sex-
ual health services and outreach services have the least overlap in values, whereas GP and other
non-sexual health specialist services “bridge” between them. GP and other non-sexual health
specialist services and outreach services share the value that the test is most likely to be used as
a screening tool to increase testing, rather than the multiple purposes of screening, diagnosis,
and guiding use of treatment, as is necessary in sexual health services. Non-specialist settings
also have similarities for evidence of cost-effectiveness and translation challenges as this often
requires new staff and training [52, 74, 75]. Sexual health services and GP and other non-spe-
cialist services overlap most for change in practice and change in resource requirement, and
implementation metrics.
Discussion
The Cepheid CT/NG GeneXpert test was the only molecular CT/NG POCT to have been
implemented and evaluated as part of routine practice in the published literature. Although it
did not meet all TPP or REASSURED criteria, review of its implementation and reported ben-
efits demonstrated this did not preclude it from bringing value to a service or its stakeholders.
Of note, although the cost-per-test of the Cepheid CT/NG GeneXpert exceeds the minimum
TPP and REASSURED recommendations [49], cost-effectiveness models show relative value-
for-money of POCTs when considering onward transmission and progression of disease [50,
75–78]. Thus, it is only when these tools and frameworks are examined within the delivery
context that sense-making happens around the adoption and implementation decision-mak-
ing processes [26, 79]. This was further emphasised when extracting these findings for devel-
opment of the value proposition, where we found that values differed both within and between
healthcare settings.
To our knowledge, this is the first report that systematically reviews the literature on molec-
ular CT/NG POCTs’ implementation in routine practice, to assess the value different stake-
holders in different settings place on them. Furthermore, we have synthesised this evidence to
Table 3. (Continued)
Care setting Study design and location Target population Test Implementation Impacts assessed Results
Assessment of GeneXpert
implementation in urban Walk In
Ruhr (WIR) inter-institutional
care centre, Germany, Dec 2016 –
July 2018. Skaletz-Rorowski et al.
2020.
Asymptomatic youth (14–30 years)
approached in schools, universities and
youth centres attending sexual health
education lectures; sample collection
took place at WIR inter-institutional
care centre
GeneXpert platform implemented
within WIR centre. Samples tested by
nurses or doctors immediately after
collection
Turn around time (TAT) was
defined as the interval
between
when the swabs were
provided to the patient to the
time communication of the
result to the patient.
1. Median turnaround time
(TAT) (time between swab
provision and patients
receiving results)
2. Time between test and
starting treatment
he interval between
initiation of test to initiation
of therapy was additionally
documented.
272 participants (133 males, 133 females).
1. Median TAT was 3:09 hours; 91.8% received
their positive test result within 24 hours, and
95.7% within 48 hours. This compares with
standard TAT of 72 hours
2. Median time between test and starting treatment
was 6:50 hours; 73.3% received initial treatment
within 24 hours, and 86.7% within 48 hours.
This compares with standard time to treatment
of approximately 120 hours
73.3% with a positive result received initial




PLOS ONE Review and value of molecular chlamydia and gonorrhoea point of care tests implemented into routine practice
PLOS ONE | https://doi.org/10.1371/journal.pone.0259593 November 8, 2021 12 / 23
Table 4. Value proposition for molecular CT/NG POCTs by setting type, based on the value proposition for laboratory medicine [35].




(Is it a service redesign issue?
Is it a quality improvement issue?
Are there any potential conflicts of
interest between stakeholders, e.g.
disinvestment in other stakeholders’
resources, e.g. alternative diagnostic
technology?)
Specialist health service (level 3)
Impact on existing resources and
contracts must be considered.
Primary health service (level 1).
If added to pre-existing services, impact
on existing resources and contracts
must be considered.
Community health service (level 0).
If added to pre-existing services, impact
on existing resources and contracts
must be considered.
Unmet need
(Is it a clinical, process, and/or economic
problem?)
Unmet need is likely to be context and stakeholder dependent.
Faster results delivery, reduced time to treatment and appropriate patient management (clinical and process).
Potential for increased timely access to sexual healthcare.
Patient acquisition of results within one visit has potential to improve CT/NG diagnosis process for patients and healthcare
professionals (i.e. via reduction of patient recall).
Care pathway context
(Is it a screening, diagnosis, or
monitoring issue?)
Screening and diagnosis: in general CT/NG tests are used either for diagnostic purposes in individual clinical cases, or for
national screening programmes. As these are not chronic conditions repeat performance of tests to monitor CT and NG
over time is not needed. However, test of cure is recommended for all patients diagnosed with NG, and for some patients
with CT.
Test and its utility(ies)
(Is it for screening, diagnosis, candidacy
for treatment, guiding use of treatment,
monitoring efficacy of, and compliance
with, treatment?)
Screening, diagnosis, guiding use of
treatment.
Can be used as a screening tool to
increase testing opportunistically among
asymptomatic patients and enables
symptomatic patients access to rapid
diagnosis and guides treatment when
needed.
Can be used as a screening tool to
increase testing among asymptomatic
populations with a high prevalence of
infection and enables access to rapid
diagnosis and guides treatment when
needed.
Resource requirement
(What will be the cost of the test? Will
there be additional resource
requirement, or redundancy, in other
parts of the organization?)
Costs of tests is likely to be higher than
laboratory tests, though cost savings
may be made in reduction of staff costs
for patient recall.
Reduction of time for healthcare
professionals to conduct patient recall.
May necessitate changes to clinical
pathways / duration of patient visit to
accommodate test time to results to
enable same-day results delivery and
treatment if needed.
Costs of tests is likely to be higher than
laboratory tests, though costs savings
may be found in reducing inappropriate
antibiotic treatment.
May necessitate changes to clinical
pathways / duration of patient visit to
accommodate test time to results to
enable same-day results delivery and
treatment if needed.
Costs of tests is likely to be higher than
laboratory tests.
Redeployment of healthcare
professionals may need to be employed
to enable outreach service.
Mobile testing van, new or existing
community space will be needed to
provide testing and treatment.
Benefits of using test
(Will it improve diagnosis and
treatment, process of care, and/or
patient experience? Will it reduce cost of
care?)
Faster time to results improves faster
time to treatment where needed which
may result in:
reduction in inappropriate treatment
(reduced syndromic treatment);
expedited partner therapy; reduction in
onward progression of disease
(sequelae).
Faster time to results improves faster
time to treatment where needed, which
may result in:
avoiding unnecessary treatment;
reduction in loss to follow-up and recall
efforts; expedited contact tracing;
onward progression of disease
(sequelae); potential for widening
testing and screening coverage.
Faster time to results improves faster
time to treatment where needed, which
may also result in:
reduction in inappropriate treatment
(reduced syndromic treatment);
reduction of onward progression of
disease (sequelae); expedited access to
treatment for contacts; potential for
widening testing and screening
coverage.
Impact on outcomes
(Will it improve patient morbidity and
mortality, access to care, and/or
efficiency of care?
Will it reduce the complications of
care?)
Potential to increase appropriate
antibiotic treatment for infections.
Potential for reduced time to results
and treatment to reduce unnecessary
antibiotic use.
Reduction in inappropriate treatment
(reduced syndromic treatment) may
reduce antibiotic resistance.
Potential to raise awareness among
healthcare professionals and thus
increase their offer of STI testing to
patients.
Potential to increase appropriate
antibiotic treatment for infections.
Potential for reduced time to results and
treatment to reduce unnecessary
antibiotic use.
Improvement in patient access to STI
testing enables earlier treatment of
previously undiagnosed infections.
Improvement in patient access to STI
testing enables earlier treatment of
previously undiagnosed infections.
Potential to increase appropriate
antibiotic treatment for infections.
(Continued)
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Table 4. (Continued)
Value proposition Sexual health services General Practice and other non-sexual
health specialist services
Outreach services
Evidence of clinical effectiveness
(Is there evidence of improved
diagnostic accuracy?
Is there is evidence of improved clinical
outcome?)
Evidence of similar accuracy to laboratory-based tests must be established.
Improved clinical outcomes including reduction in inappropriate treatment (reduced syndromic treatment); onward
progression of disease (sequelae).
Evidence of cost effectiveness
Is there evidence of cost effectiveness
when using the test?)
May reduce costs to the clinic and
reduce healthcare professional time;
cost-effectiveness models in higher-
income countries show value-for-
money when considering transmission
and progression of disease.
Cost effectiveness is likely to depend on
impact of diagnoses on larger public
health outcomes (as per specialist
service modelling).
Cost effectiveness is likely to depend on
impact of diagnoses on larger public
health outcomes (as per specialist
service modelling).
Translation challenges
(What is the plan for translating the
evidence of effectiveness into routine
practice?)
The instrument should be easy to use
and allow connectivity to existing
clinical recording systems to provide
rapid access to results.
Guidance for implementation of new
tests in services is often lacking; clinical
leads are responsible for overseeing
clinical pathway changes so
implementation is likely to be service-
driven and thus inconsistently
delivered.
The instrument should be easy to use
and allow connectivity to existing
clinical recording systems to provide
rapid access to results.
Training in equipment may be needed
prior to implementation.
Training in sexual healthcare provision
may be needed for healthcare
professionals.
The instrument should be easy to use
and allow connectivity to existing
clinical recording systems to provide
rapid access to results.
Training in equipment may be needed
prior to implementation.
Training in sexual healthcare provision
may be needed for healthcare
professionals.
Change in practice
(Will there be a revised care guideline,
e.g. revised diagnostic pathway)
Stakeholder engagement is necessary to
enable implementation.
May necessitate changes to clinical
pathways / duration of patient visit to
accommodate test time to results to
enable same-day results delivery and
treatment if needed.
Stakeholder engagement is necessary to
enable implementation.
May necessitate changes to clinical
pathways / duration of patient visit to
accommodate test time to results to
enable same-day results delivery and
treatment if needed.
Stakeholder engagement is necessary to
enable implementation.
Provision of STI / CT/NG screening
where previously none present.
Change in process
(Will there be rapid access to results,
reduction in clinic visit requirement,
care provided in different setting?)
Reduction in time to result.
Rapid access to infection-specific
treatment (for CT and/or NG positive
patients).
Reduction in time to result.
Reduction in follow-up visits for those
found positive for infection.
Provision of STI / CT/NG screening
where previously none present.
Change in resource requirement
(Will there be reduced use of alternative
diagnostic tools, reduced length of stay,
reduced need for hospitalization?)
If time to results cannot be achieved
within the standard clinical visit time,
patients will have an increased length of
stay.
The number of patients managed with
POCTs may result in the reduction of
laboratory-based CT/NG tests
conducted.
If time to results cannot be achieved
within the standard clinical visit time,
patients will have an increased length of
stay.
The number of patients managed with
POCTs may result in the reduction of
laboratory-based CT/NG tests
conducted.
Additional resources may be needed to
provide this as a new service.
(Continued)
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develop a value proposition to facilitate decision-making around their integration into sexual
healthcare. By reviewing the Cepheid CT/NG GeneXpert’s implementation, we were able to
demonstrate the diversity of use in various healthcare settings (specialist, non-specialist, and
outreach), and in different areas of the world, allowing a more robust review of the test’s value
from multiple stakeholder perspectives.
Of particular interest is the finding that sexual health specialist and outreach services had
the least overlap in values. This underlines the need for specific measures of value to be identi-
fied by service type: if a service does not already exist (as in outreach), mapping outcome mea-
sures such as costs of changes to existing clinical pathways and associated costs of task
redeployment are redundant, whereas these are clearly important measures if redesigning an
existing sexual health clinic service. Similarly, consideration of existing services provided
within specific settings matter: measuring the impact of replacing traditional laboratory CT/
NG NAATs with POCTs (including impact on current laboratory contracts) requires different
evaluation indicators than does the replacement of syndromic management of possible infec-
tions with POCTs. The examples presented here highlight our key finding: the value of novel
diagnostic test adoption and implementation is perceived differently depending on your set-
ting and stakeholder role. It is therefore critical for the values for the specific service to be iden-
tified before a test and its mode of implementation are chosen.
We did not consider studies that focused solely on test performance, or reports on test
implementation in research-use-only environments, as we considered these outside the remit
of this report. By limiting ourselves to implementation studies, we may have missed identifying
additional values of the test, although we tried to address this by including research study out-
comes in the final value proposition (Table 4). We only searched two databases (Medline and
Table 4. (Continued)




(What are the intermediate outcome
measures (clinical, process and
economic), e.g., HbA1c, new test usage,
previous test usage, time to treatment,
clinic visits, length of stay, to be
employed in performance management
of implementation)
Clinical outcome measures: number of
patients appropriately treated; number
of partner notifications averted;
number of patient follow-up visits
averted; number of patients receiving
same-day result; numbers of partners
appropriately treated.
Process outcome measures: Feasibility
and acceptability among healthcare
professionals and patients; time from
sample taking to result to patient;
impact on patient waiting times (as
compared to standard care).
Economic outcome measures: initial
costs and ongoing cost of POCT
contract, as compared with standard
care (laboratory-based testing); clinical
pathway change cost comparison, i.e.,
reduction of treatment, follow up and
contact tracing costs, any change to
staff time for testing and results
delivery (as per specialist services).
Clinical outcome measures: number of
patients appropriately treated; number
of patients receiving same-day result;
number of partners appropriately
treated.
Process outcome measures: Feasibility
and acceptability among healthcare
professionals and patients; time from
sample taking to result to patient;
impact on patient waiting times (as
compared to standard care).
Economic outcome measures: initial
costs and ongoing cost of POCT
contract, as compared with standard
care (laboratory-based testing); clinical
pathway change cost comparison, i.e.,
reduction of follow up and contact
tracing costs, any change to staff time
for testing and results delivery.
Clinical outcome measures: number
of patients appropriately treated;
number of patients receiving same-day
result; number of partners treated.
Process outcome measures: Feasibility
and acceptability among healthcare
professionals and patients; time from
sample taking to result to patient.
Economic outcome measures: cost per
screening; cost per infection detected;
total cost of service.
Accountability
(Who will benefit from use of test?
Who may experience dis-benefit?
Who will manage the implementation?)
There is potential for benefit to the health system, health care professionals, patients and the population.
Healthcare professionals will be responsible for performing the tests and managing new patient care pathways.
Potential disbenefit to population infection surveillance systems.
The number of patients managed with POCTs may result in the reduction of laboratory-based CT/NG tests conducted.
https://doi.org/10.1371/journal.pone.0259593.t004
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Embase), but given the subject area, the inclusion of conference abstracts, and the fact we
searched references of included papers, we think all relevant publications have been identified.
It is likely, however, that there are other cases of implementation that have not been reported
in the literature; publications available will most likely reflect the values of the study authors,
and not those of all stakeholders involved. Furthermore, multiple value propositions for
POCTs exist [34, 35]; we chose one, based on its relevance to laboratory medicine and inclu-
sion of diversity of stakeholder values.
We found variability between reports of implementation studies and their outcomes, as
well as in their study quality. Not all of the studies included reported on clinical pathways (i.e.
procedures), which would have outlined how the test was used. As a result, we cannot directly
compare the results of each setting, which precluded metanalysis and limits our ability to
understand the value of the test to each stakeholder in each of the different contexts. We
encourage authors to have clear objectives, to report on outcomes matching these objectives,
and to follow the appropriate international standards of reporting for their chosen study
design. However, although uniformity would enable better evaluation across different settings,
it would unlikely reflect the diversity of outcomes that need to be measured in those different
settings; the heterogeneity in study design, test implementation and impacts assessed in the lit-
erature in itself demonstrates the variability of values placed on molecular CT/NG POCTs by
different stakeholders and in different settings. For example, the inclusion of qualitative studies
in the value proposition we propose enabled us to broaden our understanding of the contex-
tual values of these POCTs. We suggest more work be done to understand the values of a
wider variety of stakeholders in order to encourage them to be actively involved in study
design and implementation, which would lead to reporting of more relevant outcomes of
interest. We also encourage reflexive reporting on lessons learned, particularly with regards to
study design and outcomes measures; if any data were found to be important when assessing
the POCTs for adoption but were not thought to be important when the evaluation was
designed, this would be useful to consider in future studies and their design.
Despite the diversity of Cepheid CT/NG GeneXpert implementation mechanisms, there
were commonalities among study outcomes to explore. Patient benefit was measured in each,
although the indicators that were measured varied, including numbers of patients who
received a same-day result, time between clinic visit and/or sample taking and result provision,
and patient acceptability. Among CT/NG positive patients, time to treatment, and partner
notification/treatment measures were also commonly reported.
Healthcare professionals are a particularly important stakeholder group for implementation
and previous research to identify an ideal test has focused on them [80]; clinicians are often
responsible for new pathway construction [52, 81], and research has shown that nurses’ inclu-
sion in quality improvement projects may improve job satisfaction and reduce workforce
instability [82]. Healthcare providers across the included studies placed value in patient bene-
fits, specifically the reduced time to result notification, and for those patients testing positive,
reduced time to treatment. Qualitative studies, in particular those among healthcare profes-
sionals participating in the TTANGO studies in Australia, reported high levels of satisfaction
with the Cepheid CT/NG GeneXpert, and related this to their belief in the test’s ability to
improve patient and public health outcomes, as well as the device’s ease of use [83, 84]. How-
ever, in some studies [61, 65], the faster time to results delivery was negatively impacted by
patients being unwilling or unable to wait for their results at the point of care; qualitative stud-
ies providing insight into the appropriate implementation of CT/NG POCTs into routine
healthcare practice may help to mitigate this issue [85].
No test fulfils all the WHO TPP or (RE)ASSURED criteria [9, 11, 12]. However, even less-
than-perfect technologies have the potential to improve patient outcomes [86, 87]; waiting for
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the ideal molecular POCT before implementing tests that are currently available has implica-
tions both for individual patients and public health [88, 89]. This research synthesis shows the
potential for less-than-perfect CT/NG POCTs to hold value for multiple stakeholders in differ-
ent healthcare settings. Therefore, we recommend that stakeholders in sexual healthcare
explore the potential for existing POCTs to provide value to their services. As more molecular
CT/NG POCTs are developed and approved by regulatory bodies, the specific characteristics
of each may be more or less suited to particular settings, and the value proposition developed
could help decision-makers determine the most important values for them and their stake-
holders to guide test choice.
Conclusions
Criteria have been set for the development of ideal CT/NG POCTs. Similarly, guidance has
been developed for the adoption of novel diagnostics into health systems. This guidance is nec-
essary to protect patients and direct health systems towards efficient use of resources to meet
public health goals, and attempts to cater to a diverse range of stakeholder needs and expecta-
tions. The plurality of these needs means that a single test is unlikely to be viewed as a panacea
or “magic bullet” for solving the clinical, social and structural issues around provision of CT/
NG diagnosis across all settings. Stakeholders wishing to improve their service through the
implementation of CT/NG POCTs should be supported to identify the values most relevant to
their settings and context rather than waiting for the ideal test to be produced: there is no
magic bullet.
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